



# Efficacy and safety of carmustine wafers, followed by radiation, temozolomide, and bevacizumab therapy, for newly diagnosed glioblastoma with maximal resection

Masayuki Kanamori<sup>1</sup> · Ichiyo Shibahara<sup>2</sup> · Yoshiteru Shimoda<sup>1</sup> · Yukinori Akiyama<sup>3</sup> · Takaaki Beppu<sup>4</sup> · Shigeo Ohba<sup>5</sup> · Toshiyuki Enomoto<sup>6</sup> · Takahiro Ono<sup>7</sup> · Yuta Mitobe<sup>8</sup> · Mitsuto Hanihara<sup>9</sup> · Yohei Mineharu<sup>10</sup> · Joji Ishida<sup>11</sup> · Kenichiro Asano<sup>12</sup> · Yasuyuki Yoshida<sup>13</sup> · Manabu Natsumeda<sup>14</sup> · Sadahiro Nomura<sup>15</sup> · Tatsuya Abe<sup>16</sup> · Hajime Yonezawa<sup>17</sup> · Ryuichi Katakura<sup>18</sup> · Soichiro Shibui<sup>19</sup> · Toshihiko Kuroiwa<sup>20</sup> · Hiroyoshi Suzuki<sup>21</sup> · Hidehiro Takei<sup>22</sup> · Haruo Matsushita<sup>23</sup> · Ryuta Saito<sup>1,24</sup> · Yoshiki Arakawa<sup>10</sup> · Yukihiko Sonoda<sup>8</sup> · Yuichi Hirose<sup>5</sup> · Toshihiro Kumabe<sup>2</sup> · Takuhiro Yamaguchi<sup>25</sup> · Hidenori Endo<sup>1</sup> · Teiji Tominaga<sup>1</sup>

Received: 18 July 2024 / Accepted: 22 October 2024  
© The Author(s) 2024

## Abstract

**Background** To improve the outcome in newly diagnosed glioblastoma patients with maximal resection, we aimed to evaluate the efficacy and safety of implantation of carmustine wafers (CWs), radiation concomitant with temozolomide and bevacizumab, and maintenance chemotherapy with six cycles of temozolomide and bevacizumab.

**Method** This prospective phase II study enrolled glioblastoma patients considered candidates for complete resection (> 90%) of a contrast-enhanced lesion. The CWs were intraoperatively implanted into the resection cavity after achieving maximal resection. Patients without a measurable contrast-enhanced lesion on magnetic resonance imaging within 48 h after resection received concomitant radiotherapy and chemotherapy with temozolomide and bevacizumab, followed by maintenance treatment with up to six cycles of temozolomide and bevacizumab. The primary endpoint was the 2-year overall survival rate in glioblastoma patients with protocol treatment.

**Results** From October 2015 to April 2018, we obtained consent for the first registration from 70 patients across 17 institutions in Japan, and 49 patients were treated according to the protocol. We evaluated the safety in 49 patients who were part of the second registration and the efficacy in 45 glioblastoma patients treated according to the protocol. The profile of hematological and most of the non-hematological adverse effects was similar to that in previous studies, but stroke occurred in 12% of cases (6/49 patients). The estimated 2-year overall survival rate was 51.3%.

**Conclusion** Implantation of CWs, followed by concomitant radiation, temozolomide, and bevacizumab, and six cycles of temozolomide and bevacizumab may offer some benefit to survival in Japanese glioblastoma patients with maximal resection.

**Trial ID** jRCTs021180007.

**Keywords** Glioblastoma · Maximal resection · Temozolomide · Carmustine wafers · Bevacizumab

## Introduction

Glioblastoma is the most malignant primary parenchymal tumor in adults. A randomized phase III trial by the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada Clinical Trials Group (NCIC) reported improved median overall survival (OS) for patients with glioblastoma treated with

concomitant and adjuvant temozolomide and radiotherapy. This treatment, called Stupp's regimen, is the standard treatment for newly diagnosed glioblastoma [1]. Even with standard treatment, however, glioblastoma has a poor prognosis with a median OS of 14.6 months and a 2-year survival rate of 26.5% [1].

Extent of resection (EOR) is an important prognostic factor in the treatment of glioblastoma, and several retrospective studies of large numbers of cases report a correlation between the EOR of contrast-enhanced (CE) lesions and prognosis [2, 3]. The 2-year survival rate of

Extended author information available on the last page of the article

combined treatment after complete resection was 38.4% in the EORTC-NCIC clinical trial [1], however, suggesting that more effective treatment modalities for patients with maximal EOR are needed.

Carmustine wafer (CW) implantation intensifies local therapy. Double-blind placebo-controlled studies conducted before the temozolomide era demonstrated that CW implantation prolongs survival in newly diagnosed and recurrent malignant gliomas [4, 5]. Despite the lack of prospective data demonstrating an additive effect of CWs on radiation and temozolomide in newly diagnosed glioblastoma, a large French retrospective study demonstrated that CW implantation prolongs progression-free survival (PFS) in patients with total and subtotal resection [6]. Thus, this treatment is expected to be particularly effective in cases with a high EOR [7].

Vascular endothelial growth factor (VEGF) has angiogenic and vascular permeability-enhancing effects at sites of ischemia [8]. Bevacizumab is a humanized anti-VEGF antibody that normalizes blood vessels, decreases tissue interstitial pressure, and induces tissue reoxygenation by inhibiting abnormal angiogenesis and reducing vascular permeability [9, 10]. Synergistic effects of bevacizumab on other chemotherapeutic agents are expected through reoxygenation, and additive effects of bevacizumab in combination with several other agents have been examined [10]. Two placebo-controlled, double-blind, clinical trials were conducted to examine the effect of bevacizumab on temozolomide and radiotherapy in newly diagnosed glioblastoma [11, 12]. Both trials failed to demonstrate an OS benefit but showed an increase in PFS in the bevacizumab groups [11, 12]. A systematic review, however, reported that a combination of chemotherapeutic agents and bevacizumab had a modest effect on OS [13]. The additive effect of bevacizumab on CW implantation and temozolomide has not yet been prospectively examined. Instead of multiple combination treatments with carmustine, temozolomide, and bevacizumab, we reduced the number of cycles of maintenance treatment to avoid complications associated with the long-term administration of temozolomide and bevacizumab, such as myelodysplastic syndrome and acute myeloid leukemia after temozolomide [14]; and stroke [15], hypertension, and proteinuria [16] after bevacizumab.

This phase II study evaluated the efficacy and safety of CW implantation in combination with concomitant radiotherapy, temozolomide, and bevacizumab, and maintenance treatment limited to six cycles in patients with newly diagnosed glioblastoma who had no residual measurable disease after tumor resection according to the Response Assessment in Neuro-Oncology criteria (RANO) [17] in all registered patients.

## Methods

### Patients

We applied for a two-step registration. The inclusion criteria for the first registration were as follows: age 20–75 years, suspicion of supratentorial glioblastoma on preoperative gadolinium-enhanced T1-weighted magnetic resonance (MR) imaging (Gd-T1WI), and expectation for achieving an EOR  $\geq$  90% of the CE lesion. Patients were secondarily registered within 3–20 days after tumor resection. The inclusion criteria for the second registration were as follows: histological diagnosis of glioblastoma according to the fourth edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System [18]; performance status (PS) of 0, 1, 2, or 3 on the Eastern Cooperative Oncology Group performance status (ECOG-PS) scale; and no measurable CE lesions based on RANO criteria [17] detected on Gd-T1WI within 72 h after tumor resection. The eligibility criteria for systemic conditions are provided in the Supplementary files.


### Treatment protocol

Maximal and safe resection of the CE lesion on Gd-T1WI was performed. After confirming the pathological diagnosis of malignant glioma during surgery, one to eight CWs were implanted in the resection cavity. Within 21 days after tumor resection, patients received radiotherapy and temozolomide. Bevacizumab was also intravenously administered three times (Fig. 1A). In the maintenance chemotherapy phase, combination therapy with temozolomide and bevacizumab was started 4 weeks after ending the concomitant treatment and administered for six cycles (Fig. 1B).

### Patient evaluation and follow-up

The central histopathological diagnoses for all patients were reviewed according to the fourth edition of the WHO Classification of Tumours of the Central Nervous System [18] by consensus of two board-certified pathologists (H.S., H.T.).

Before the first and second registration and during protocol treatment and follow-up, patients underwent a physical examination, including subjective and objective symptoms, evaluation of Karnofsky Performance Status (KPS) and ECOG-PS, neurological examinations, blood cell counts, serum chemical examination, and urine examination. MR imaging was performed within 7 days before the first registration, within 72 h after tumor resection, and between the last day of concomitant radiation and chemotherapy and the



**Fig. 1** Treatment protocol of this study. **A** Concurrent radiation and chemotherapy phase. Within 21 days after maximal and safe tumor resection and implantation of carmustine wafers, patients received radiotherapy (60 Gy/30 fractions) as 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy concomitantly with temozolomide (75 mg/m<sup>2</sup>, daily) from the first to last day of radiation therapy. Bevacizumab was also intravenously administered

at a dose of 10 mg/kg, on day 1 of weeks 4, 6, and 8 after initiation of the radiation and temozolomide therapy. **B** Maintenance chemotherapy phase. Combination therapy with temozolomide (100–200 mg/m<sup>2</sup> per day on days 1–5) and intravenous bevacizumab (10 mg/kg, on days 1 and 15 of each cycle) were started 4 weeks after ending the concomitant treatment and administered for 6 cycles (24 weeks)

first day of maintenance treatment. Thereafter, MR imaging was performed every 8 weeks.

### Statistical analysis

The primary endpoint was the 2-year OS rate in all patients with glioblastoma treated according to the protocol. OS is defined as the time from the second registration to death from any cause and was censored on the last day on which the patient was confirmed to be alive. Secondary endpoints were PFS, local PFS (LPFS), KPS deterioration-free survival time in all patients with glioblastoma treated according to protocol, and the incidence of adverse events (AE) and severe AEs in all registered patients. PFS was defined as the time from the second registration to disease progression or death from any cause and was censored the last day on which the patient was confirmed to be alive without any evidence of disease progression. Progression was defined according to the RANO criteria [17] (Supplementary file) and assessed by local neurosurgeons. The definitions of LPFS and KPS deterioration-free survival time are provided in the Supplementary file. AEs were evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.

We assumed an expected 2-year survival rate of 50% and a threshold 2-year survival rate of 35%, which were derived from patients who underwent gross total resection of the CE lesion and received concomitant radiation and temozolomide therapy with adjuvant temozolomide in the EORTC-NCIC study [19]. To obtain a power of 80% with a

one-sided significance level of 5% for the 24-month registration and 36-month observation periods, 44 patients were required. Considering the number of patient withdrawals and exclusions at the second registration, the total target sample size was 55 patients. The Kaplan–Meier method was used to analyze the survival rate, and 90% confidence intervals (CIs) were calculated using the Greenwood formula. Because the number of patients was lower than initially predicted, we extended the registration period from 2 to 2.5 years and changed the significance level from 5 to 10%.


### DNA analysis

To elucidate the background of glioblastoma, *IDH1* and *IDH2* gene mutations; the *MGMT* gene promoter methylation status; and copy number alterations (CNAs) of *epidermal growth factor receptor (EGFR)*, *cyclin-dependent kinase inhibitor 2A (CDKN2A)*, and *phosphatase and tensin homolog deleted from chromosome 10 (PTEN)* gene were evaluated as previously described (Supplementary file) [20–22].

## Results

### Patients

Patient flow through the study is shown in Fig. 2. From October 2015 to April 2018, 70 patients from 17 institutes provided their consent to participate in the study, and the



**Fig. 2** Patient flow in this study

first registration was conducted. At the second registration, 21 patients were not eligible for registration for the reasons shown in Fig. 2. Thus, 49 cases were treated according to the protocol and analyzed for compliance and safety. Of these 49 cases, 4 were excluded from the analysis for efficacy; 2 patients received 12 cycles of maintenance temozolomide and bevacizumab, which was regarded as a protocol violation; and 2 patients were diagnosed with anaplastic ependymoma and anaplastic astrocytoma at the central pathological diagnosis. All 49 patients were of Asian ethnicity and Japanese nationality. The background of the 45 patients analyzed for efficacy is shown in Table 1.

### Protocol treatment compliance

Of the 49 cases, 16 (33%) completed the protocol treatment without any cessation or discontinuation of radiation therapy, temozolomide, or bevacizumab, and 43 (88%) cases completed 6 cycles of maintenance protocol treatment with cessation of chemotherapy or discontinuation of either radiation, temozolomide, or bevacizumab. Details of the protocol treatment compliance are provided in the Supplemental file.

### Primary and secondary outcome


Of the 45 glioblastoma patients treated according to protocol, 23 died during the study period. The estimated 2-year survival rate was 51.3% with an 80% CI of 40.8–60.9% (Fig. 3A). Median OS was 24.8 months (80% CI 19.7–36.4 months), with an OS rate of 34.2% at 45 months from the date of enrollment; 39 patients showed progression

**Table 1** Patient demographics

	Number of patients (%)
Age (median) (mean)	33–75 (64.0) (59.7)
Sex	
Male	23 (51.1)
Female	22 (48.9)
ECOG PS at first registration	
0	9 (20.0)
1	17 (37.8)
2	9 (20.0)
3	10 (22.2)
KPS at first registration	
100	5 (11.1)
90	16 (35.6)
80	4 (8.9)
70	7 (15.6)
60	8 (17.8)
50	3 (6.7)
40	2 (4.4)

*ECOG PS*, European Clinical Oncology Group performance status; *KPS* Karnofsky performance status

during the study period. The median PFS was 11.8 months (80% CI 10.5–13.3 months) (Fig. 3B), and the PFS rate at 39 months from the date of the definitive registration was 8.5%. Of the 39 cases with recurrence, 7 (18%) cases had distant recurrence and 32 (82%) had local recurrence. LPFS and KPS deterioration-free survival rates are shown in Supplementary Fig. 1.



**Fig. 3** Overall survival (OS) (A) and progression-free survival (PFS) (B) rate in 45 glioblastoma patients who received protocol treatment. The 2-year OS rate was 51.3%. The median OS and PFS were 25 months and 11 months, respectively

**Adverse events**

Table 2 provides a summary of the AEs observed in this study. All deaths were ruled out as causally related to

protocol treatment during the study period.

Adverse effects known to occur with CWs and bevacizumab included proteinuria in 8 (16%), seizure in 6 (13%), cerebrovascular ischemia in 6 (12%), hypertension in 4 (8%),

**Table 2** Summary of adverse effects (number of patients with adverse effects) in 49 registered patients

	All grades (%)*	Grade 3 or 4 (%)
Any adverse effects	44 (90)	26 (53)
Hematological adverse effects		
Any hematological adverse effects	33 (67)	15 (31)
Anemia	16 (33)	1 (2)
Lymphocyte count decreased	18 (37)	10 (20)
Neutrophil count decreased	17 (37)	9 (18)
Platelet count decreased	7 (14)	2 (4)
Non-hematological adverse effects		
Any non-hematological adverse effects	40 (82)	17 (35)
Fever	2 (4)	0
Wound dehiscence	1 (2)	0
Seizure	6 (12)	3 (6)
Hypertension	4 (8)	2 (2)
Proteinuria	8 (16)	3 (6)
Mucocutaneous bleeding	0	0
Apatite loss	7 (14)	1 (2)
Hyponatremia	5 (10)	0
Hyperkalemia	2 (4)	1 (2)
Allergic reaction	2 (4)	0
Infections and infestations	5 (10)	1 (2)
AST increased	8 (16)	1 (2)
ALT increased	5 (10)	0
Creatinine increased	2 (4)	0
Hydrocephalus	1 (2)	1 (2)
Cerebrovascular ischemia	6 (12)	2 (4)

\*Assessed by Common Terminology Criteria for Adverse Effects version 4.0

AST aspartate aminotransferase, ALT alanine aminotransferase



and wound dehiscence in 1 (2%). Cerebrovascular ischemia occurred between 8 and 25 months (median 14 months) after the second registration despite the short course of bevacizumab; cerebrovascular ischemia occurred in 5 patients after completion of the protocol therapy and in 1 patient during the maintenance phase.

### Survival by the MGMT gene promoter methylation status and CNA of EGFR, CDKN2A, and PTEN genes

The molecular profiles of our patients are shown in Supplementary Table 1. Median OS was not reached within the median follow-up period of 28.6 and 20.0 months in patients with methylated and unmethylated *MGMT* gene promoters, respectively (Supplementary Fig. 2). CNAs had no impact on the OS rate (data not shown).

## Discussion

In this multicenter phase II trial, Japanese patients with newly diagnosed glioblastoma who were candidates for complete resection (>90%) of CE lesions were treated with maximal resection and CW implantation. Patients with no residual measurable CE lesion received concurrent treatment with radiation, temozolomide, and bevacizumab, and maintenance treatment was limited to six cycles of temozolomide and bevacizumab. The 2-year survival rate of 51.3% meets the prespecified criteria of a 2-year survival rate of >50.0% in this study. This is the first prospective study demonstrating the result of maximal resection of newly diagnosed glioblastoma in Asian patients.

Compared to the subgroup analysis of patients with complete resection in the EORTC-NCIC study, which reported a 2-year survival rate of 38.4%, and in the EF-14 study, which demonstrated the effect of tumor treating fields with a median survival time of 22.6 months [23], this treatment was considered potentially beneficial. A similar regimen was examined in a retrospective study from a single Japanese institution [24]. Akiyama et al. reported a median OS of 24.2 months in patients treated with Stupp's regimen plus CWs and bevacizumab [24]. Although maintenance therapy was continued until recurrence in their study, the patient background characteristics, including the EOR, were similar between our study and theirs (no measurable lesion vs 96%; mean age 59.7 years vs 62.2 years; and mean pretreatment KPS 76.6 vs 76.7), and the median OS was comparable. A study published in 2018, however, reported a significantly longer survival time in Asian glioblastoma patients than in Hispanic patients based on a large population [25]. This difference was explained by a difference in the proportion of cases with *EGFR* gene abnormalities or with *EGFR*, *CDKN2A*, and *PTEN* gene abnormalities [22, 26].

CNA analysis in the present study revealed that the CNA profiles of the *EGFR*, *CDKN2A*, and *PTEN* genes and the proportions of cases with CNAs for all three genes were similar to those of the Japanese cohort and significantly different from those of the TCGA cohort [22] (Supplementary Table 1). Therefore, because previous reports were limited to subgroup analysis, the results of this study should be compared to those of an Asian glioblastoma population with maximal resection [24, 27–34] (Supplementary Table 2). First, we reviewed previous reports in which the PFS and OS after maximal resection followed by Stupp's regimen were reported based on more than 50 Asian patients [27–32]. Among these reports, the median OS exceeded 24 months in three studies [28–30]. In these studies, 52–58 patients were analyzed, and maximal resection was defined as 100% [29, 30] and >99% [28] resection of CE lesions. In contrast, the median OS was 21.0 and 23.0 months in the large series from Korea [27] and China [32], respectively. Second, we reviewed the PFS and OS after maximal resection followed by Stupp's regimen and CW implantation. The median OS in patients treated with CWs in combination with Stupp's regimen was 22.3 months in a multicenter retrospective study [33] and 27.3 months in a postmarketing study that included patients under 70 years of age [34]. Based on those reports, adding the combination of CWs and bevacizumab to Stupp's regimen or Stupp's regimen and CW implantation could provide an additional benefit for OS. It is difficult to draw a definitive conclusion about the positive effects of adding CWs and bevacizumab, however, because of the large variability in this study (80% CI for median survival time: 19.7–36.4 months) and the unknown prognostic factors, such as *MGMT* promoter methylation status, KPS, and age, due to the subgroup analysis in previous reports.

A meta-analysis of clinical trials conducted in the United States and Europe found no effect of bevacizumab on survival in cases with methylated and unmethylated *MGMT* gene promoters [35]. Hata et al., however, demonstrated an additive effect of bevacizumab to Stupp's regimen on OS in Japanese patients only with an unmethylated *MGMT* gene promoter [36]. In addition, Grossmann et al. reported an additive effect of CWs on OS in patients with a methylated *MGMT* gene promoter [37]. To explore whether the *MGMT* gene promoter methylation status affected the OS outcome of the combination of CW implantation and bevacizumab on glioblastoma, we compared our results to those of a multicenter retrospective study in Korean glioblastoma patients with total resection followed by Stupp's regimen, in which the median OS was 28.6 months and 19.0 months in patients with methylated and unmethylated *MGMT* gene promoters, respectively [27]. While the median OS was comparable to that following Stupp's regimen in patients with an unmethylated *MGMT* gene promoter (20.1 months vs 19.0 months), median OS in patients with a methylated

*MGMT* gene promoter in the present study seems better (OS rate at 28.6 months: 74.0% vs 50%). Although these results were also obtained from the subgroup analysis and further analysis is required, CW implantation combined with bevacizumab might have an additive effect on Stupp's regimen in patients with a methylated *MGMT* gene promoter. The addition of CW implantation to Stupp's regimen was associated with longer PFS only in patients with subtotal or total resection [6] and improved local tumor control [38, 39]. A randomized control study demonstrated that the addition of bevacizumab to Stupp's regimen was associated with longer PFS only in patients with tumor resection [6]. Based on these results, we expected that the addition of CWs and bevacizumab could lead to a significant improvement in PFS, and that the proportion of local recurrence would be decreased by maximum resection of gadolinium-enhanced lesions followed by CW implantation [33]. Only modest differences, however, were observed in the median PFS time and PFS rate at 2 years compared with previous reports (Supplementary Table 2) and 82% of the patients experienced local recurrence. We presumed that a short course of bevacizumab in the maintenance phase could be associated with a short median PFS because PFS time was prolonged when bevacizumab was continued until progression in clinical trials evaluating the addition of bevacizumab to Stupp's regimen [6] and in a retrospective analysis of the addition of CW implantation and bevacizumab to Stupp's regimen [24]. In this study, several factors may have contributed to the lack of a reduction in local recurrence. First, some reports demonstrated that resection must be performed beyond the gadolinium-enhanced lesion to reduce local recurrence [40, 41]. We did not collect data on the EOR of non-enhanced lesions in this study, but it is possible that the EOR was not sufficient to reduce local recurrence. Second, although a study by the French Neurosurgical Society demonstrated that CW implantation prolongs PFS in patients with subtotal and total resection of gadolinium-enhanced lesions based on a large number of patients, the effect of CWs on the pattern of recurrence remains unclear, especially in patients with total resection of gadolinium-enhanced lesions. Third, the effects of bevacizumab on the pattern of failure are also unclear. Although bevacizumab does not affect the pattern of recurrence [42, 43], its impact on the pattern of failure remains unknown [44].

In the present study, neutropenia and thrombocytopenia  $\geq$  grade 3 were observed in 18% and 4% of patients, respectively. The incidence was comparable to that reported by the EORTC-NCIC (7% and 12%, respectively) and the JCOG 0911 (neutropenia: 16.2%) studies. The combination of CWs and bevacizumab could increase wound dehiscence. This complication was observed in only one patient (2%), comparable to the result of Stupp's regimen (1.2–4.9%), Stupp's regimen plus bevacizumab (2.6–6.9%), and Stupp's

regimen plus CW implantation (1.6–3.3%) [11, 12, 33, 34]. Limited cycles of maintenance treatment with bevacizumab and temozolomide could lead to a decrease in proteinuria, hyperextension, and mucocutaneous bleeding compared to previous reports [11, 12, 45] in which proteinuria (15.6–29.8%), hypertension (39.3–42.6%), and mucocutaneous bleeding (1.7–10.6%) were reported. Cerebrovascular ischemia, however, occurred more frequently (12%) than in previous reports reporting ischemic complications: 1.9% of cases from previous clinical trials with bevacizumab and other antiangiogenic agents [15] and 5.9–7.4% of cases in prospective clinical studies of Stupp's regimen and bevacizumab [11, 45]. The combination of CWs and radiation, temozolomide, and bevacizumab itself could increase this complication by an unknown mechanism. Otherwise, considering that this complication occurred after completion of the maintenance phase in five of six cases, it might be due to salvage treatment.

The present study has some limitations. First, among the 70 patients initially enrolled, 21 (30%) did not proceed to the second registration. The most frequent reason was pathological diagnosis other than glioblastoma in 12 cases (17%), but we experienced 6 (8.5%) patients who did not proceed to second registration for reasons related to surgery, including delayed wound healing, pulmonary embolus, and residual lesion in 2 cases (2.9%). Second, information on salvage treatment is lacking. The protocol was limited to six courses of maintenance temozolomide and bevacizumab. In contrast to previous clinical trials of bevacizumab for newly diagnosed glioblastoma in which bevacizumab was administered until progression, limited cycles of bevacizumab in this study may lead to the early detection of recurrence. In addition, 88% of the patients were able to complete at least part of the planned treatment. These results suggest that the patients might have a chance to receive a rechallenge of temozolomide and bevacizumab at recurrence, and the effect of salvage treatment could significantly affect the outcome. An analysis of salvage treatment might have clarified the mechanism underlying the excellent OS. Third, this study included patients without measurable enhanced lesions on postoperative MR images. Quantitative estimation of the CE lesion's EOR or residual volume is required for comparison with other studies, as shown in Supplementary Table 2.

## Conclusion

This phase II study demonstrated the efficacy and safety of CW implantation followed by concomitant radiation, temozolomide, and bevacizumab, and six cycles of temozolomide and bevacizumab in patients with newly diagnosed glioblastoma. Although the hematological AE was identical to that of Stupp's regimen, strokes frequently occurred. This is the

first prospective study demonstrating the result of maximal resection of newly diagnosed glioblastoma in Asian patients. The addition of CW and bevacizumab to Stupp's regimen might provide an additional benefit for survival in Japanese glioblastoma patients with maximal resection.

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s10147-024-02650-9>.

**Acknowledgements** The authors thank all of the participants. We also thank the Clinical Research, Innovation, and Education Center, Tohoku University Hospital.

**Author contributions** Conceptualization: Masayuki Kanamori, Ryuta Saito, Yoshiki Arakawa, Yukihiko Sonoda, Yuichi Hirose, Toshihiro Kumabe, and Teiji Tominaga. Supervision: Ryuichi Katakura, Soichiro Shibui, Toshihiko Kuroiwa, Haruo Matsushita, Hidenori Endo, and Teiji Tominaga. Data acquisition: Masayuki Kanamori, Ichiyo Shibahara, Yoshiteru Shimoda, Yukinori Akiyama, Takaaki Beppu, Shigeo Ohba, Toshiyuki Enomoto, Takahiro Ono, Yuta Mitobe, Mitsuto Hanihara, Yohei Mineharu, Joji Ishida, Kenichiro Asano, Yasuyuki Yoshida, Manabu Natsumeda, Sadahiro Nomura, Tatsuya Abe, Hajime Yonezawa, Ryuta Saito, Yoshiki Arakawa, Yukihiko Sonoda, Yuichi Hirose, Toshihiro Kumabe. Data analysis: Masayuki Kanamori, Hiroyoshi Suzuki, Hidehiro Takei. Writing the manuscript: Masayuki Kanamori. Statistical analysis and interpretation: Masayuki Kanamori, Takuhito Yamaguchi. All authors have seen and approved the manuscript.

**Funding** Funds for this study were provided by Eisai, Co., Ltd.

**Data availability** The datasets used in the present study are available from the corresponding author upon request. All data generated or analyzed in this study are included in this published article. M. Kanamori had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

## Declarations

**Conflict of interest** Masayuki Kanamori received a grant from Eisai Co. Ltd., and lecture honoraria from Eisai Co. Ltd. and Novocure Co. Ltd. Ichiyo Shibahara received lecture honoraria from Eisai Co. Ltd. and Novocure Co. Ltd. Yoshiteru Shimoda received a grant from Eisai Co. Ltd. Shigeo Ohba received lecture honoraria from Eisai Co. Ltd., and Novocure Co. Ltd. Toshiyuki Enomoto received lecture honoraria from Eisai Co. Ltd. and Novocure Co. Ltd. Mitsuto Hanihara received lecture honoraria from Eisai Co. Ltd. Yohei Mineharu received lecture honoraria from Eisai Co. Ltd., and Novocure Co. Ltd. Joji Ishida received lecture honoraria from Eisai Co. Ltd. Kenichiro Asano received lecture honoraria from Eisai Co. Ltd. Yasuyuki Yoshida received lecture honoraria from Eisai Co. Ltd. Manabu Natsumeda received lecture honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., and Novocure Co. Ltd., and support for travel for the conference from Eisai Co. Ltd., and Novocure Co. Ltd. Tatsuya Abe received grant from Chugai Pharmaceutical Co., Ltd. and lecture honoraria from Chugai Pharmaceutical Co., Ltd. and Novocure Co. Ltd. Hajime Yonezawa received lecture honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., and Novocure Co. Ltd. Soichiro Shibui received lecture honoraria from Chugai Pharmaceutical Co., Ltd. Ryuta Saito received lecture honoraria from Eisai Co. Ltd. and Novocure Co. Ltd. Yoshiki Arakawa received grant from Chugai Pharmaceutical Co., Ltd. and Eisai Co. Ltd. and lecture honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., Nippon Kayaku, and Novocure Co. Ltd. Yukihiko Sonoda received lecture honoraria from Chugai Pharmaceutical Co.,

Ltd., Eisai Co. Ltd., and Novocure Co. Ltd. Yuichi Hirose received a grant from Eisai Co. Ltd. and honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., and Novocure Co. Ltd. Toshihiro Kumabe received lecture honoraria and travel support from Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., and Novocure Co. Ltd. Hidenori Endo received a grant from Eisai Co. Ltd. Teiji Tominaga received a grant from Eisai Co. Ltd. and honoraria from Chugai Pharmaceutical Co., Ltd., Eisai Co. Ltd., Nippon Kayaku, MSD, and Novocure Co. Ltd. Yukinori Akiyama, Takaaki Beppu, Yuta Mitobe, Takahiro Ono, Sadahiro Nomura, Ryuichi Katakura, Toshihiko Kuroiwa, Hiroyoshi Suzuki, Hidehiro Takei, and Haruo Matsushita have no conflict of interest.

**Ethical approval** The study was conducted in accordance with the Declaration of Helsinki and the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects. The Institutional Review Board of Tohoku University provided approval for the study (CRB2200003). The Institutional Review Board of Tohoku University Hospital provided approval for the molecular analysis (2015-2-126-1, 2023-1-971).

**Informed consent statement** Informed consent was obtained from all subjects involved in the study.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References


1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. *N Engl J Med* 352(10):987–996. <https://doi.org/10.1056/NEJMo043330>. (PMID: 15758009)
2. Sanai N, Polley MY, McDermott MW et al (2011) An extent of resection threshold for newly diagnosed glioblastomas. *J Neurosurg* 115(1):3–8. <https://doi.org/10.3171/2011.2.jns.10998>. (Epub 2011 Mar 18 PMID: 21417701)
3. Marko NF, Weil RJ, Schroeder JL et al (2014) Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. *J Clin Oncol*. 32(8):774–782. <https://doi.org/10.1200/JCO.2013.51.8886>. (PMID: 24516010; PMID: PMC4876349)
4. Brem H, Piantadosi S, Burger PC et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas The Polymer-brain Tumor Treatment Group. *Lancet* 345(8956):1008–1012. [https://doi.org/10.1016/s0140-6736\(95\)90755-6](https://doi.org/10.1016/s0140-6736(95)90755-6). (PMID: 7723496)
5. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (*Gliadel wafers*) in patients with primary malignant glioma. *Neuro Oncol* 5(2):79–88. <https://doi.org/10.1093/neuonc/5.2.79>. (PMID:12672279; PMID:PMC1920672)



6. Pallud J, Audureau E, Noel G et al (2015) Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. *Neuro Oncol.* 17(12):1609–19. <https://doi.org/10.1093/neuonc/nov126>. (Epub 2015 Jul 16. PMID: 26185110; PMCID: PMC4633930)
7. Kadota T, Saito R, Kumabe T et al (2019) A multicenter randomized phase III study for newly diagnosed maximally resected glioblastoma comparing carmustine wafer implantation followed by chemoradiotherapy with temozolomide with chemoradiotherapy alone; Japan Clinical Oncology Group Study JCOG1703 (MACS study). *Jpn J Clin Oncol.* 49(12):1172–1175. <https://doi.org/10.1093/jcco/hyz169>
8. Conway EM, Collen D, Carmeliet P (2001) Molecular mechanisms of blood vessel growth. *Cardiovasc Res* 49(3):507–521. [https://doi.org/10.1016/s0008-6363\(00\)00281-9](https://doi.org/10.1016/s0008-6363(00)00281-9). (PMID: 11166264)
9. Carmeliet P, Jain RK (2011) Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. *Nat Rev Drug Discov* 10(6):417–427. <https://doi.org/10.1038/nrd3455>. (PMID: 21629292)
10. Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. *Cancer Cell* 6(6):553–563. <https://doi.org/10.1016/j.ccr.2004.10.011>. (PMID: 15607960)
11. Chinot OL, Wick W, Mason W et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. *N Engl J Med* 370(8):709–722. <https://doi.org/10.1056/NEJMoa1308345>. (PMID: 24552318)
12. Gilbert MR, Dignam JJ, Armstrong TS et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med* 370(8):699–708. <https://doi.org/10.1056/NEJMoa1308573>. (PMID:24552317; PMCID:PMC4201043)
13. Ameratunga M, Pavlakis N, Wheeler H et al (2018) Anti-angiogenic therapy for high-grade glioma. *Cochrane Database Syst Rev.* 11(11):CD008218. <https://doi.org/10.1002/14651858.CD008218.pub4>. (PMID: 30480778; PMCID: PMC6516839)
14. Kim SJ, Park TS, Lee ST et al (2009) Therapy-related myelodysplastic syndrome/acute myeloid leukemia after treatment with temozolomide in a patient with glioblastoma multiforme. *Ann Clin Lab Sci* 39(4):392–398 (PMID: 19880768)
15. Fraum TJ, Kreisl TN, Sul J et al (2011) Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. *J Neurooncol.* 105(2):281–289. <https://doi.org/10.1007/s11060-011-0579-4>. (Epub 2011 Apr 27. PMID: 21603965; PMCID: PMC3168718)
16. Oda Y, Shih JH, Kreisl TN et al (2014) Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort. *J Neurooncol.* 120(2):431–440 (Epub 2014 Aug 7. PMID: 25098701)
17. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. *J Clin Oncol.* 28(11):1963–1972. <https://doi.org/10.1200/JCO.2009.26.3541>. (Epub 2010 Mar 15. PMID: 20231676)
18. Louis DN, Ohgaki H, Wiestler OD et al (2007) The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol.* 114(2):97–109. <https://doi.org/10.1007/s00401-007-0243-4>. (Epub 2007 Jul 6. Erratum in: *Acta Neuropathol.* 2007;114(5):547. PMID: 17618441; PMCID: PMC1929165)
19. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. *Lancet Oncol* 10(5):459–466. [https://doi.org/10.1016/S1470-2045\(09\)70025-7](https://doi.org/10.1016/S1470-2045(09)70025-7). (Epub 2009 Mar 9 PMID: 19269895)
20. Sonoda Y, Kumabe T, Nakamura T et al (2009) Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. *Cancer Sci* 100(10):1996–1998. <https://doi.org/10.1111/j.1349-7006.2009.01270.x>. (PMID: 19765000)
21. Sonoda Y, Kumabe T, Watanabe M et al (2009) Long-term survivors of glioblastoma: clinical features and molecular analysis. *Acta Neurochir (Wien)* 151(11):1349–1358. <https://doi.org/10.1007/s00701-009-0387-1>. (PMID: 19730774)
22. Umehara T, Arita H, Yoshioka E et al (2019) Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts. *Acta Neuropathol Commun* 7(1):99. <https://doi.org/10.1186/s40478-019-0749-8>. (Erratum. In: *Acta Neuropathol Commun.* 2019Aug14;7(1):131. PMID:31215469; PMCID:PMC6580599)
23. Stupp R, Taillibert S, Kanner A et al (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. *JAMA* 318(23):2306–2316. <https://doi.org/10.1001/jama.2017.18718>. (PMID:29260225; PMCID:PMC5820703)
24. Akiyama Y, Kimura Y, Enatsu R et al (2018) Advantages and disadvantages of combined chemotherapy with carmustine wafer and bevacizumab in patients with newly diagnosed glioblastoma: a single-institutional experience. *World Neurosurg* 113:e508–e514. <https://doi.org/10.1016/j.wneu.2018.02.070>. (Epub 2018 Feb 21 PMID: 29476996)
25. Bohn A, Braley A, Rodriguez de la Vega P et al (2018) The association between race and survival in glioblastoma patients in the US: a retrospective cohort study. *PLoS One.* 13(6):e0198581
26. Lassman AB, Aldape KD, Ansell PJ et al (2019) Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma. *J Neurooncol* 144(1):205–210
27. Kim BS, Seol HJ, Nam DH et al (2017) Concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide for newly diagnosed glioblastoma patients: a retrospective multicenter observation study in Korea. *Cancer Res Treat.* 49(1):193–203. <https://doi.org/10.4143/crt.2015.473>. (Epub 2016 Jun 27. PMID: 27384161; PMCID: PMC5266397)
28. Joo JD, Chang JH, Kim JH et al (2012) Temozolomide during and after radiotherapy for newly diagnosed glioblastoma: a prospective multicenter study of Korean patients. *J Korean Neurosurg Soc.* 52(2):92–97. <https://doi.org/10.3340/jkns.2012.52.2.92>. (Epub 2012 Aug 31. PMID: 23091665; PMCID: PMC3467382)
29. Woo PYM, Ho JMK, Tse TPK et al (2019) Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: a multicenter cohort study. *J Clin Neurosci* 63:134–141. <https://doi.org/10.1016/j.jocn.2019.01.022>. (Epub 2019 Jan 31 PMID: 30712777)
30. Ishikawa E, Sugii N, Matsuda M et al (2021) Maximum resection and immunotherapy improve glioblastoma patient survival: a retrospective single-institution prognostic analysis. *BMC Neurol* 21(1):282. <https://doi.org/10.1186/s12883-021-02318-1>. (PMID:34281518; PMCID:PMC8287820)
31. Ahn S, Park JS, Song JH et al (2020) Effect of a time delay for concomitant chemoradiation after surgery for newly diagnosed glioblastoma: a single-institution study with subgroup analysis according to the extent of tumor resection. *World Neurosurg* 133:e640–e645. <https://doi.org/10.1016/j.wneu.2019.09.122>. (Epub 2019 Sep 27 PMID: 31568907)
32. Jiang H, Zeng W, Ren X et al (2019) Super-early initiation of temozolomide prolongs the survival of glioblastoma patients

- without gross-total resection: a retrospective cohort study. *J Neurooncol* 144(1):127–135. <https://doi.org/10.1007/s11060-019-03211-1>. (Epub 2019 Jun 7 PMID: 31175579)
33. Sonoda Y, Shibahara I, Matsuda KI et al (2017) Opening the ventricle during surgery diminishes survival among patients with newly diagnosed glioblastoma treated with carmustine wafers: a multi-center retrospective study. *J Neurooncol* 134(1):83–88. <https://doi.org/10.1007/s11060-017-2488-7>. (Epub 2017 May 22 PMID: 28534151)
  34. Iuchi T, Inoue A, Hirose Y et al (2022) Long-term effectiveness of Gliadel implant for malignant glioma and prognostic factors for survival: 3-year results of a postmarketing surveillance in Japan. *Neurooncol Adv*. 4(1):vdab189. <https://doi.org/10.1093/nojnl/vdab189>. (PMID: 35118382; PMCID: PMC8807118)
  35. Du C, Ren J, Zhang R et al (2016) Effect of bevacizumab plus temozolomide-radiotherapy for newly diagnosed glioblastoma with different mgmt methylation status: a meta-analysis of clinical trials. *Med Sci Monit* 22(22):3486–3492. <https://doi.org/10.12659/msm.899224>. (PMID:27684457; PMCID:PMC5045921)
  36. Hata N, Mizoguchi M, Kuga D et al (2020) First-line bevacizumab contributes to survival improvement in glioblastoma patients complementary to temozolomide. *J Neurooncol* 146(3):451–458. <https://doi.org/10.1007/s11060-019-03339-0>. (Epub 2020 Feb 4 PMID: 32020475)
  37. Grossman R, Burger P, Soudry E et al (2015) MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel. *J Clin Neurosci* 22(12):1938–1942. <https://doi.org/10.1016/j.jocn.2015.07.003>. (Epub 2015 Aug 4 PMID: 26249244)
  38. Shimato S, Nishizawa T, Ohshima T et al (2016) Patterns of recurrence after resection of malignant gliomas with BCNU wafer implants: retrospective review in a single institution. *World Neurosurg* 90:340–347. <https://doi.org/10.1016/j.wneu.2016.02.102>. (Epub 2016 Mar 4 PMID: 26960286)
  39. Shibahara I, Miyasaka K, Sekiguchi A et al (2021) Long-term follow-up after BCNU wafer implantation in patients with newly diagnosed glioblastoma. *J Clin Neurosci* 86:202–210. <https://doi.org/10.1016/j.jocn.2021.01.037>. (Epub 2021 Feb 10 PMID: 33775329)
  40. Tejada S, Aldave G, Marigil M et al (2014) Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. *J Neurooncol*. 116(1):169–75. <https://doi.org/10.1007/s11060-013-1279-z>. (Epub 2013 Oct 18. Erratum in: *J Neurooncol*. 2014 Jan;116(1):177. de Gallego, Jaime [corrected to Gállego Pérez-Larraya, Jaime]. PMID: 24135848; PMCID: PMC3889292)
  41. De Bonis P, Anile C, Pompucci A et al (2013) The influence of surgery on recurrence pattern of glioblastoma. *Clin Neurol Neurosurg* 115(1):37–43. <https://doi.org/10.1016/j.clineuro.2012.04.005>. (Epub 2012 Apr 24 PMID: 22537870)
  42. Chamberlain MC (2011) Radiographic patterns of relapse in glioblastoma. *J Neurooncol* 101(2):319–323. <https://doi.org/10.1007/s11060-010-0251-4>. (Epub 2010 Jun 10 PMID: 21052776)
  43. Cachia D, Elshafeey NA, Kamiya-Matsuoka C et al (2017) Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. *J Neurooncol* 135(1):75–81. <https://doi.org/10.1007/s11060-017-2550-5>. (Epub 2017 Jul 12 PMID: 28702781)
  44. Duntze J, Litré CF, Eap C et al (2013) Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. *Ann Surg Oncol* 20(6):2065–2072. <https://doi.org/10.1245/s10434-012-2764-x>. (Epub 2012 Dec 2 PMID: 23212763)
  45. Nagane M, Ichimura K, Onuki R et al (2022) Bevacizumab beyond progression for newly diagnosed glioblastoma (BIOMARK): phase II safety, efficacy and biomarker study. *Cancers (Basel)* 14(22):5522. <https://doi.org/10.3390/cancers14225522>. PMID: 36428615; PMCID: PMC9688169
- Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Authors and Affiliations

Masayuki Kanamori<sup>1</sup>  · Ichiyo Shibahara<sup>2</sup> · Yoshiteru Shimoda<sup>1</sup> · Yukinori Akiyama<sup>3</sup> · Takaaki Beppu<sup>4</sup> · Shigeo Ohba<sup>5</sup> · Toshiyuki Enomoto<sup>6</sup> · Takahiro Ono<sup>7</sup> · Yuta Mitobe<sup>8</sup> · Mitsuto Hanihara<sup>9</sup> · Yohei Mineharu<sup>10</sup> · Joji Ishida<sup>11</sup> · Kenichiro Asano<sup>12</sup> · Yasuyuki Yoshida<sup>13</sup> · Manabu Natsumeda<sup>14</sup> · Sadahiro Nomura<sup>15</sup> · Tatsuya Abe<sup>16</sup> · Hajime Yonezawa<sup>17</sup> · Ryuichi Katakura<sup>18</sup> · Soichiro Shibui<sup>19</sup> · Toshihiko Kuroiwa<sup>20</sup> · Hiroyoshi Suzuki<sup>21</sup> · Hidehiro Takei<sup>22</sup> · Haruo Matsushita<sup>23</sup> · Ryuta Saito<sup>1,24</sup> · Yoshiki Arakawa<sup>10</sup> · Yukihiko Sonoda<sup>8</sup> · Yuichi Hirose<sup>5</sup> · Toshihiro Kumabe<sup>2</sup> · Takuhiro Yamaguchi<sup>25</sup> · Hidenori Endo<sup>1</sup> · Teiji Tominaga<sup>1</sup>

✉ Masayuki Kanamori  
mkanamori@med.tohoku.ac.jp

<sup>1</sup> Department of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Japan

<sup>2</sup> Department of Neurosurgery, Kitasato University School of Medicine, Sagami, Japan

<sup>3</sup> Department of Neurosurgery, Sapporo Medical University School of Medicine, Sapporo, Japan

<sup>4</sup> Department of Neurosurgery, Iwate Medical University, Shiwa, Japan

<sup>5</sup> Department of Neurosurgery, Fujita Health University, Toyoake, Japan

<sup>6</sup> Department of Neurosurgery, Fukuoka University, Fukuoka, Japan

<sup>7</sup> Department of Neurosurgery, Akita University Graduate School of Medicine, Akita, Japan

<sup>8</sup> Department of Neurosurgery, Faculty of Medicine, Yamagata University, Yamagata, Japan

<sup>9</sup> Department of Neurosurgery, Graduate School of Medicine, University of Yamanashi, Yamanashi, Japan

<sup>10</sup> Department of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Japan

<sup>11</sup> Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

- <sup>12</sup> Department of Neurosurgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
- <sup>13</sup> Department of Neurosurgery, St. Marianna University School of Medicine, Kawasaki, Japan
- <sup>14</sup> Department of Neurosurgery, Niigata University Brain Research Institute, Niigata, Japan
- <sup>15</sup> Department of Neurosurgery, Yamaguchi University School of Medicine, Ube, Japan
- <sup>16</sup> Department of Neurosurgery, Faculty of Medicine, Saga University, Saga, Japan
- <sup>17</sup> Department of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
- <sup>18</sup> Department of Neurosurgery, Miyagi Cancer Center, Natori, Japan
- <sup>19</sup> Department of Neurosurgery, Teikyo University Hospital, Kawasaki, Japan
- <sup>20</sup> Department of Neurosurgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
- <sup>21</sup> Department of Pathology and Laboratory Medicine, National Hospital Organization Sendai Medical Center, Miyagi, Japan
- <sup>22</sup> Department of Pathology and Laboratory Medicine, University of Texas, Houston, USA
- <sup>23</sup> Department of Radiation Oncology, Tohoku University Graduate School of Medicine, Sendai, Japan
- <sup>24</sup> Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
- <sup>25</sup> Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan